Radioimmunoimaging of xenograft pancreatic cancer with 131I-monoclonal antibody P2

Zheng Yao Chong Zheng Yao, G. J. Poston, J. Ishizuka, Courtney Townsend, J. C. Thompson

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Monoclonal antibodies (McAbs) to pancreatic cancer were developed by fusing SP2/0 cells and splenocytes from Balb/c mice immunized with CH-2 cells. The specific binding rates of McAb P1 and P2 were 40.1 and 43.8%, respectively, shown by binding radioreactivity assay in vitro, which were in sharp contrast with those of control groups (p < 0.05). The biodistribution of radioiodinated McAb P2 was studied by measuring parameters of tumor- specific radioreactivity in nude mice bearing CH-2 tumors. The ratios of tumors to nontumors were all >2 at 48 h. The localization index of cancer and the ratio of tumor to pancreas were 4.05 and 4.16, respectively, at 72 h. Therefore, 131I-McAbs may be useful for radioimmunoimaging (RII) of pancreatic cancer. After intraperitoneal injection of 131I-McAb P2 into tumor-bearing nude mice, imaging of xenograft pancreatic cancer became increasingly distinct with the nonspecific background fading, especially in the period of 72-96 h. Examination of pancreatic cancer tissues by immunohistochemical methods revealed that McAb P2 was strongly positive (86%) in comparison with other tumors and normal tissues. The results demonstrated that clinical RII of pancreatic cancer was feasible with McAb P2.

Original languageEnglish (US)
Pages (from-to)289-294
Number of pages6
JournalPancreas
Volume8
Issue number3
StatePublished - 1993

Fingerprint

Radioimmunodetection
Pancreatic Neoplasms
Heterografts
Monoclonal Antibodies
Neoplasms
Intraperitoneal Injections
Nude Mice
Pancreas
Control Groups

Keywords

  • Localization index
  • Monoclonal antibody
  • Pancreatic cancer
  • Radioimmunoimaging
  • Tumor/nontumor ratio
  • Xenograft tumor

ASJC Scopus subject areas

  • Endocrinology
  • Gastroenterology

Cite this

Chong Zheng Yao, Z. Y., Poston, G. J., Ishizuka, J., Townsend, C., & Thompson, J. C. (1993). Radioimmunoimaging of xenograft pancreatic cancer with 131I-monoclonal antibody P2. Pancreas, 8(3), 289-294.

Radioimmunoimaging of xenograft pancreatic cancer with 131I-monoclonal antibody P2. / Chong Zheng Yao, Zheng Yao; Poston, G. J.; Ishizuka, J.; Townsend, Courtney; Thompson, J. C.

In: Pancreas, Vol. 8, No. 3, 1993, p. 289-294.

Research output: Contribution to journalArticle

Chong Zheng Yao, ZY, Poston, GJ, Ishizuka, J, Townsend, C & Thompson, JC 1993, 'Radioimmunoimaging of xenograft pancreatic cancer with 131I-monoclonal antibody P2', Pancreas, vol. 8, no. 3, pp. 289-294.
Chong Zheng Yao ZY, Poston GJ, Ishizuka J, Townsend C, Thompson JC. Radioimmunoimaging of xenograft pancreatic cancer with 131I-monoclonal antibody P2. Pancreas. 1993;8(3):289-294.
Chong Zheng Yao, Zheng Yao ; Poston, G. J. ; Ishizuka, J. ; Townsend, Courtney ; Thompson, J. C. / Radioimmunoimaging of xenograft pancreatic cancer with 131I-monoclonal antibody P2. In: Pancreas. 1993 ; Vol. 8, No. 3. pp. 289-294.
@article{5149250e35e54372b9c25a23b638527a,
title = "Radioimmunoimaging of xenograft pancreatic cancer with 131I-monoclonal antibody P2",
abstract = "Monoclonal antibodies (McAbs) to pancreatic cancer were developed by fusing SP2/0 cells and splenocytes from Balb/c mice immunized with CH-2 cells. The specific binding rates of McAb P1 and P2 were 40.1 and 43.8{\%}, respectively, shown by binding radioreactivity assay in vitro, which were in sharp contrast with those of control groups (p < 0.05). The biodistribution of radioiodinated McAb P2 was studied by measuring parameters of tumor- specific radioreactivity in nude mice bearing CH-2 tumors. The ratios of tumors to nontumors were all >2 at 48 h. The localization index of cancer and the ratio of tumor to pancreas were 4.05 and 4.16, respectively, at 72 h. Therefore, 131I-McAbs may be useful for radioimmunoimaging (RII) of pancreatic cancer. After intraperitoneal injection of 131I-McAb P2 into tumor-bearing nude mice, imaging of xenograft pancreatic cancer became increasingly distinct with the nonspecific background fading, especially in the period of 72-96 h. Examination of pancreatic cancer tissues by immunohistochemical methods revealed that McAb P2 was strongly positive (86{\%}) in comparison with other tumors and normal tissues. The results demonstrated that clinical RII of pancreatic cancer was feasible with McAb P2.",
keywords = "Localization index, Monoclonal antibody, Pancreatic cancer, Radioimmunoimaging, Tumor/nontumor ratio, Xenograft tumor",
author = "{Chong Zheng Yao}, {Zheng Yao} and Poston, {G. J.} and J. Ishizuka and Courtney Townsend and Thompson, {J. C.}",
year = "1993",
language = "English (US)",
volume = "8",
pages = "289--294",
journal = "Pancreas",
issn = "0885-3177",
publisher = "Lippincott Williams and Wilkins",
number = "3",

}

TY - JOUR

T1 - Radioimmunoimaging of xenograft pancreatic cancer with 131I-monoclonal antibody P2

AU - Chong Zheng Yao, Zheng Yao

AU - Poston, G. J.

AU - Ishizuka, J.

AU - Townsend, Courtney

AU - Thompson, J. C.

PY - 1993

Y1 - 1993

N2 - Monoclonal antibodies (McAbs) to pancreatic cancer were developed by fusing SP2/0 cells and splenocytes from Balb/c mice immunized with CH-2 cells. The specific binding rates of McAb P1 and P2 were 40.1 and 43.8%, respectively, shown by binding radioreactivity assay in vitro, which were in sharp contrast with those of control groups (p < 0.05). The biodistribution of radioiodinated McAb P2 was studied by measuring parameters of tumor- specific radioreactivity in nude mice bearing CH-2 tumors. The ratios of tumors to nontumors were all >2 at 48 h. The localization index of cancer and the ratio of tumor to pancreas were 4.05 and 4.16, respectively, at 72 h. Therefore, 131I-McAbs may be useful for radioimmunoimaging (RII) of pancreatic cancer. After intraperitoneal injection of 131I-McAb P2 into tumor-bearing nude mice, imaging of xenograft pancreatic cancer became increasingly distinct with the nonspecific background fading, especially in the period of 72-96 h. Examination of pancreatic cancer tissues by immunohistochemical methods revealed that McAb P2 was strongly positive (86%) in comparison with other tumors and normal tissues. The results demonstrated that clinical RII of pancreatic cancer was feasible with McAb P2.

AB - Monoclonal antibodies (McAbs) to pancreatic cancer were developed by fusing SP2/0 cells and splenocytes from Balb/c mice immunized with CH-2 cells. The specific binding rates of McAb P1 and P2 were 40.1 and 43.8%, respectively, shown by binding radioreactivity assay in vitro, which were in sharp contrast with those of control groups (p < 0.05). The biodistribution of radioiodinated McAb P2 was studied by measuring parameters of tumor- specific radioreactivity in nude mice bearing CH-2 tumors. The ratios of tumors to nontumors were all >2 at 48 h. The localization index of cancer and the ratio of tumor to pancreas were 4.05 and 4.16, respectively, at 72 h. Therefore, 131I-McAbs may be useful for radioimmunoimaging (RII) of pancreatic cancer. After intraperitoneal injection of 131I-McAb P2 into tumor-bearing nude mice, imaging of xenograft pancreatic cancer became increasingly distinct with the nonspecific background fading, especially in the period of 72-96 h. Examination of pancreatic cancer tissues by immunohistochemical methods revealed that McAb P2 was strongly positive (86%) in comparison with other tumors and normal tissues. The results demonstrated that clinical RII of pancreatic cancer was feasible with McAb P2.

KW - Localization index

KW - Monoclonal antibody

KW - Pancreatic cancer

KW - Radioimmunoimaging

KW - Tumor/nontumor ratio

KW - Xenograft tumor

UR - http://www.scopus.com/inward/record.url?scp=0027483070&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027483070&partnerID=8YFLogxK

M3 - Article

VL - 8

SP - 289

EP - 294

JO - Pancreas

JF - Pancreas

SN - 0885-3177

IS - 3

ER -